Ironwood Pharmaceuticals Inc
NASDAQ:IRWD

Watchlist Manager
Ironwood Pharmaceuticals Inc Logo
Ironwood Pharmaceuticals Inc
NASDAQ:IRWD
Watchlist
Price: 4.9314 USD -4.06% Market Closed
Market Cap: $802.2m

Operating Margin

42.4%
Current
Improving
by 3.5%
vs 3-y average of 38.9%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
42.4%
=
Operating Income
$143.7m
/
Revenue
$339m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
42.4%
=
Operating Income
$143.7m
/
Revenue
$339m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Ironwood Pharmaceuticals Inc
NASDAQ:IRWD
802m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Higher than 95% of companies in the United States of America
Percentile
95th
Based on 14 112 companies
95th percentile
42.4%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Ironwood Pharmaceuticals Inc
Glance View

Ironwood Pharmaceuticals, Inc. is a healthcare company, which focuses on the development and commercialization of Gastrointestinal (GI) product opportunities in areas of significant unmet need, leveraging demonstrated expertise and capabilities in GI diseases. The company is headquartered in Boston, Massachusetts and currently employs 219 full-time employees. The company went IPO on 2010-02-03. The company operates in the human therapeutics business segment. Its product candidate LINZESS (linaclotide) is available to adult men and women suffering from IBS-C or CIC in the United States, and Mexico and to adult men and women suffering from IBS-C. Its linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC in Canada, and to adult men and women suffering from IBS-C in certain European countries. The Company’s products pipeline includes IW-3300, which is a GC-C agonist, for the potential treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis, and CNP-104 is a tolerizing immune modifying nanoparticle.

IRWD Intrinsic Value
8.0318 USD
Undervaluation 39%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
42.4%
=
Operating Income
$143.7m
/
Revenue
$339m
What is Ironwood Pharmaceuticals Inc's current Operating Margin?

The current Operating Margin for Ironwood Pharmaceuticals Inc is 42.4%, which is above its 3-year median of 38.9%.

How has Operating Margin changed over time?

Over the last 3 years, Ironwood Pharmaceuticals Inc’s Operating Margin has decreased from 56.7% to 42.4%. During this period, it reached a low of 23.2% on Mar 31, 2025 and a high of 61% on Dec 31, 2022.

Back to Top